[
  {
    "date": "2022-06-29",
    "symbol": "SGBI",
    "period": "FY",
    "entitycentralindexkey": 1104280,
    "currentfiscalyearenddate": "--06-30",
    "entityregistrantname": "SANGUI BIOTECH INTERNATIONAL INC",
    "documenttype": "10-K",
    "documentperiodenddate": "2022-06-30",
    "entitytaxidentificationnumber": "84-1330732",
    "entityfilercategory": "Non-accelerated Filer",
    "entitycurrentreportingstatus": "Yes",
    "entityinteractivedatacurrent": "Yes",
    "entityvoluntaryfilers": "No",
    "entitywellknownseasonedissuer": "No",
    "entityshellcompany": "false",
    "entitysmallbusiness": "true",
    "entityemerginggrowthcompany": "false",
    "documentannualreport": "true",
    "entityfilenumber": "0-21271",
    "entityaddressstateorprovince": "CO",
    "entityincorporationstatecountrycode": "CO",
    "entityaddressaddressline1": "Bleichenbrücke 9",
    "entityaddresscityortown": "Hamburg",
    "entityaddresscountry": "DE",
    "entityaddresspostalzipcode": 20354,
    "countryregion": 49,
    "cityareacode": 40,
    "localphonenumber": 6093120,
    "amendmentflag": "false",
    "documentfiscalyearfocus": 2022,
    "documentfiscalperiodfocus": "FY",
    "documenttransitionreport": "false",
    "auditorfirmid": 3627,
    "auditorname": "Sadler, Gibb &amp; Associates, LLC",
    "auditorlocation": "Draper, UT",
    "cash": 30469,
    "prepaidexpensecurrent": 11822,
    "accountsandotherreceivablesnetcurrent": 1979,
    "accountsreceivablenetcurrent": 13312,
    "duefromrelatedpartiescurrent": 10127,
    "assetscurrent": 67709,
    "propertyplantandequipmentnet": 358,
    "leaseholdimprovementsgross": 62721,
    "assets": 130788,
    "accountspayableandotheraccruedliabilitiescurrent": 128385,
    "duetorelatedpartiescurrent": 72365,
    "notespayablecurrent": 11290,
    "debtcurrent": 707696,
    "operatingleaseliabilitycurrent": 15883,
    "liabilitiescurrent": 935619,
    "operatingleaseliabilitynoncurrent": 41228,
    "longtermnotespayable": 48898,
    "liabilitiesnoncurrent": 90126,
    "liabilities": 1025745,
    "commonstockvalue": 33124956,
    "additionalpaidincapital": 4513328,
    "treasurystockcommonvalue": 19387,
    "accumulatedothercomprehensiveincomelossnetoftax": 96600,
    "retainedearningsaccumulateddeficit": -37954625,
    "stockholdersequity": -239128,
    "minorityinterest": -655829,
    "stockholdersequityincludingportionattributabletononcontrollinginterest": -894957,
    "liabilitiesandstockholdersequity": 130788,
    "preferredstocksharesauthorized": 10000000,
    "commonstocksharesauthorized": 250000000,
    "commonstocksharesissued": 209955598,
    "commonstocksharesoutstanding": 209901842,
    "revenues": 69190,
    "grossprofit": 69190,
    "researchanddevelopmentexpense": 8565,
    "professionalfees": 146096,
    "generalandadministrativeexpense": 53205,
    "depreciationandamortization": 770,
    "operatingexpenses": 208636,
    "operatingincomeloss": -139446,
    "foreigncurrencytransactiongainlossbeforetax": 99722,
    "interestexpensedebt": 19364,
    "lossonsettlementonaccountspayable": 4254,
    "nonoperatingincomeexpense": 76104,
    "incomelossfromcontinuingoperationsbeforeincometaxesdomestic": -63342,
    "profitloss": -63342,
    "incomelossfromcontinuingoperationsattributabletononcontrollingentity": 4032,
    "netincomeloss": -59310,
    "othercomprehensiveincomelossforeigncurrencytransactionandtranslationadjustmentnetoftax": 6930,
    "othercomprehensiveincomelosstax": -56412,
    "basicanddilutedweightedaveragenumberofsharesoutstanding": 208604727,
    "sharesoutstanding": 209955598,
    "proceedsfromissuanceofcommonstock": 28345,
    "stockissuedduringperiodsharesnewissues": 2616556,
    "commonstockissuedtosettleaccountspayable": 8435,
    "commonstockissuedtosettleaccountspayableshares": 383444,
    "othercomprehensiveincomelossforeigncurrencytranslationadjustmenttax": 6930,
    "foreigncurrencytransactiongainlossunrealized": 99722,
    "gainslossesonextinguishmentofdebt": -4182,
    "amortizationofrighttouseasset": -20733,
    "increasedecreaseinaccountsreceivable": -1505,
    "increasedecreaseinprepaidexpense": 11709,
    "increasedecreaseinothercurrentassets": -46,
    "increasedecreaseinaccountspayabletrade": 15551,
    "increasedecreaseinduetootherrelatedpartiescurrent": -5211,
    "increasedecreaseinaccountspayablerelatedparties": 13980,
    "increasedecreaseinleaseacquisitioncosts": 17239,
    "netcashprovidedbyusedinoperatingactivities": -140456,
    "proceedsfromrelatedpartydebt": 46445,
    "proceedsfromnotespayable": 68686,
    "repaymentsofnotespayable": 1136,
    "netcashprovidedbyusedinfinancingactivities": 142340,
    "effectofexchangerateoncashcashequivalentsrestrictedcashandrestrictedcashequivalents": -1183,
    "cashcashequivalentsrestrictedcashandrestrictedcashequivalentsperiodincreasedecreaseexcludingexchangerateeffect": 701,
    "cashandcashequivalentsatcarryingvalue": 30469,
    "interestpaid": 999,
    "capitalleaseobligationsincurred": 24110,
    "initialrightofuseoperatingliabilities": 13563,
    "commonstockissuedforsettleaccountspayables": 8436,
    "equitymethodinvestmentownershippercentage": 0.9,
    "equitymethodinvestmentadditionalinformation": "Effective from June 18, 2018 Sangui BioTech GmbH together with Mölnlycke Health Care GmbH (former: Sastomed GmbH) founded Sangui Know-How- und Patentverwertungsgesellschaft mbH &amp; Co. KG (“Sangui KG”). Sangui KG is a limited partnership, with Sangui BioTech GmbH as the general partner (owing 99.8%) and Mölnlycke Health Care GmbH as a limited partner (owning 0.2%)",
    "foreigncurrencyexchangeratetranslation1": 0.9538,
    "depreciation": 770,
    "concentrationriskpercentage1": 1,
    "propertyplantandequipmentgross": 2938,
    "accumulateddepreciationdepletionandamortizationpropertyplantandequipment": 2580,
    "debtinstrumentinterestratestatedpercentage": 0.02,
    "interestexpense": 18345,
    "noninterestexpensedirectorsfees": 82621,
    "duetorelatedpartiesnoncurrent": 675000,
    "duetootherrelatedpartiesnoncurrent": 707696,
    "sharesissuedpricepershare": 0.0119,
    "temporaryequitystockissuedduringperiodvaluenewissues": 11867,
    "treasurystockcommonshares": 53756,
    "treasurystockvalue": 19387,
    "operatinglosscarryforwards": 31300000,
    "operatinglosscarryforwardslimitationsonuse": "The federal and state carryforward amounts expire in varying amounts between 2022 and 2032.",
    "deferredtaxassetsoperatinglosscarryforwards": 7981955,
    "deferredtaxassetsother": 130273,
    "deferredtaxliabilitiesdeferredexpensedeferredfinancingcosts": 10500,
    "deferredtaxassetstaxdeferredexpensereservesandaccrualsimpairmentlosses": 269541,
    "deferredtaxliabilitiesderivatives": 5892,
    "deferredtaxassetsvaluationallowance": 7564293,
    "lesseeoperatingleasedescription": "The Company leases office facilities from an unrelated third party at 1,172Euros ($1,229) per month. The office lease contract is beginning in January 2020 and expired June 2026.",
    "operatingleasesfutureminimumpaymentsduecurrent": 12279,
    "operatingleasesfutureminimumpaymentsdueintwoyears": 12500,
    "operatingleasesfutureminimumpaymentsdueinthreeyears": 12725,
    "operatingleasesfutureminimumpaymentsduethereafter": 12953,
    "operatingleasesfutureminimumpaymentsdue": 50457,
    "leaseandrentalexpense": 2028,
    "operatingleaseliability": 48429,
    "lesseeoperatingleasediscountrate": 0.02,
    "lesseeoperatingleaseremainingleaseterm": "P3Y8M15D",
    "sharebasedcompensationarrangementbysharebasedpaymentawarddescription": "the Board was authorized to issue up to 1,000,000 shares of common stock to certain eligible employees of the Company or its subsidiaries. All of these shares were issued pursuant to the plan prior to June 30, 2007"
  },
  {
    "date": "2021-06-29",
    "symbol": "SGBI",
    "period": "FY",
    "entitycentralindexkey": 1104280,
    "currentfiscalyearenddate": "--06-30",
    "entityregistrantname": "SANGUI BIOTECH INTERNATIONAL INC",
    "documenttype": "10-K",
    "documentperiodenddate": "2021-06-30",
    "entitytaxidentificationnumber": "84-1330732",
    "entityfilercategory": "Non-accelerated Filer",
    "entitycurrentreportingstatus": "Yes",
    "entityinteractivedatacurrent": "Yes",
    "entityvoluntaryfilers": "No",
    "entitywellknownseasonedissuer": "No",
    "entityshellcompany": "false",
    "entitysmallbusiness": "true",
    "entityemerginggrowthcompany": "false",
    "documentannualreport": "true",
    "entityfilenumber": "0-21271",
    "entityaddressstateorprovince": "CO",
    "entityincorporationstatecountrycode": "CO",
    "entityaddressaddressline1": "Bleichenbrücke 9",
    "entityaddresscityortown": "Hamburg",
    "entityaddresscountry": "DE",
    "entityaddresspostalzipcode": 20354,
    "countryregion": 49,
    "cityareacode": 40,
    "localphonenumber": 6093120,
    "amendmentflag": "false",
    "documentfiscalyearfocus": 2021,
    "documentfiscalperiodfocus": "FY",
    "documenttransitionreport": "false",
    "cash": 29768,
    "prepaidexpensecurrent": 12020,
    "accountsandotherreceivablesnetcurrent": 2286,
    "accountsreceivablenetcurrent": 16631,
    "duefromrelatedpartiescurrent": 5961,
    "assetscurrent": 66666,
    "propertyplantandequipmentnet": 1215,
    "leaseholdimprovementsgross": 66241,
    "assets": 134122,
    "accountspayableandotheraccruedliabilitiescurrent": 127311,
    "duetorelatedpartiescurrent": 62485,
    "debtcurrent": 752508,
    "operatingleaseliabilitycurrent": 12403,
    "liabilitiescurrent": 954707,
    "operatingleaseliabilitynoncurrent": 54740,
    "liabilities": 1009447,
    "commonstockvalue": 33088176,
    "additionalpaidincapital": 4513328,
    "treasurystockcommonvalue": 19387,
    "accumulatedothercomprehensiveincomelossnetoftax": 89670,
    "retainedearningsaccumulateddeficit": -37895315,
    "stockholdersequity": -223528,
    "minorityinterest": -651797,
    "stockholdersequityincludingportionattributabletononcontrollinginterest": -875325,
    "liabilitiesandstockholdersequity": 134122,
    "preferredstocksharesauthorized": 10000000,
    "commonstocksharesauthorized": 250000000,
    "commonstocksharesissued": 206955598,
    "commonstocksharesoutstanding": 206901842,
    "revenues": 65585,
    "grossprofit": 65585,
    "researchanddevelopmentexpense": 8266,
    "professionalfees": 158962,
    "generalandadministrativeexpense": 48679,
    "depreciationandamortization": 816,
    "operatingexpenses": 216723,
    "operatingincomeloss": -151138,
    "foreigncurrencytransactiongainlossbeforetax": -34585,
    "interestexpensedebt": 17987,
    "nonoperatingincomeexpense": -52572,
    "incomelossfromcontinuingoperationsbeforeincometaxesdomestic": -203710,
    "profitloss": -203710,
    "incomelossfromcontinuingoperationsattributabletononcontrollingentity": 4820,
    "netincomeloss": -198890,
    "othercomprehensiveincomelossforeigncurrencytransactionandtranslationadjustmentnetoftax": -2237,
    "othercomprehensiveincomelosstax": -205947,
    "weightedaveragenumberofshareoutstandingbasicanddiluted": 204191664,
    "sharesoutstanding": 206955598,
    "proceedsfromissuanceofcommonstock": 60500,
    "stockissuedduringperiodsharesnewissues": 3600000,
    "othercomprehensiveincomelossforeigncurrencytranslationadjustmenttax": -2237,
    "foreigncurrencytransactiongainlossunrealized": -34585,
    "amortizationofrighttouseasset": 19100,
    "increasedecreaseinaccountsreceivable": 6773,
    "increasedecreaseinprepaidexpense": 2161,
    "increasedecreaseinothercurrentassets": -5131,
    "increasedecreaseinaccountspayabletrade": 7389,
    "increasedecreaseinduetootherrelatedpartiescurrent": 1783,
    "increasedecreaseinaccountspayablerelatedparties": 16528,
    "increasedecreaseinleaseacquisitioncosts": -19665,
    "netcashprovidedbyusedinoperatingactivities": -145847,
    "proceedsfromrelatedpartydebt": 101515,
    "netcashprovidedbyusedinfinancingactivities": 162015,
    "effectofexchangerateoncashandcashequivalents": -1682,
    "cashandcashequivalentsperiodincreasedecrease": 14486,
    "cashandcashequivalentsatcarryingvalue": 29768,
    "capitalleaseobligationsincurred": 8700,
    "equitymethodinvestmentownershippercentage": 0.9,
    "equitymethodinvestmentadditionalinformation": "Effective from June 18, 2018 Sangui BioTech GmbH together with Mölnlycke Health Care GmbH (former: Sastomed GmbH) founded Sangui Know-How- und Patentverwertungsgesellschaft mbH &amp; Co. KG (“Sangui KG”). Sangui KG is a limited partnership, with Sangui BioTech GmbH as the general partner (owing 99.8%) and Mölnlycke Health Care GmbH as a limited partner (owning 0.2%).",
    "foreigncurrencyexchangeratetranslation1": 0.843845,
    "depreciation": 816,
    "concentrationriskpercentage1": 1,
    "propertyplantandequipmentgross": 3321,
    "accumulateddepreciationdepletionandamortizationpropertyplantandequipment": 2106,
    "debtinstrumentinterestratestatedpercentage": 0.02,
    "interestexpense": 17965,
    "noninterestexpensedirectorsfees": 79907,
    "duetorelatedpartiesnoncurrent": 635000,
    "duetootherrelatedpartiesnoncurrent": 752508,
    "sharesissuedpricepershare": 0.0168,
    "temporaryequitystockissuedduringperiodvaluenewissues": 60500,
    "liabilityofsharesissued": 38048,
    "treasurystockcommonshares": 53756,
    "treasurystockvalue": 19387,
    "operatinglosscarryforwards": 33100000,
    "operatinglosscarryforwardslimitationsonuse": "The federal and state carryforward amounts expire in varying amounts between 2021 and 2031.",
    "deferredtaxassetsoperatinglosscarryforwards": 7964745,
    "deferredtaxassetsother": 130273,
    "deferredtaxliabilitiesdeferredexpensedeferredfinancingcosts": 10500,
    "deferredtaxassetstaxdeferredexpensereservesandaccrualsimpairmentlosses": 269541,
    "deferredtaxliabilitiesderivatives": 5892,
    "deferredtaxassetsvaluationallowance": 7547083,
    "lesseeoperatingleasedescription": "The Company leases office facilities from an unrelated third party at 1,131 Euros ($1,348) per month. The office lease contract is beginning in January 2020 and expired June 2026.",
    "reimbursementofcostsincurred": 10868,
    "operatingleasesfutureminimumpaymentsduecurrent": 13633,
    "operatingleasesfutureminimumpaymentsdueintwoyears": 13878,
    "operatingleasesfutureminimumpaymentsdueinthreeyears": 14128,
    "operatingleasesfutureminimumpaymentsduethereafter": 29026,
    "operatingleasesfutureminimumpaymentsdue": 70665,
    "leaseandrentalexpense": 3522,
    "operatingleaseliability": 67143,
    "lesseeoperatingleasediscountrate": 0.02,
    "lesseeoperatingleaseremainingleaseterm": "P5Y",
    "sharebasedcompensationarrangementbysharebasedpaymentawarddescription": "the Board was authorized to issue up to 1,000,000 shares of common stock to certain eligible employees of the Company or its subsidiaries. All of these shares were issued pursuant to the plan prior to June 30, 2007"
  },
  {
    "date": "2020-06-29",
    "symbol": "SGBI",
    "period": "FY",
    "entitycentralindexkey": 1104280,
    "currentfiscalyearenddate": "--06-30",
    "entityregistrantname": "SANGUI BIOTECH INTERNATIONAL INC",
    "documenttype": "10-K",
    "documentperiodenddate": "2020-06-30",
    "entitytaxidentificationnumber": "84-1330732",
    "entityfilercategory": "Non-accelerated Filer",
    "entitycurrentreportingstatus": "Yes",
    "entityinteractivedatacurrent": "Yes",
    "entityvoluntaryfilers": "No",
    "entitywellknownseasonedissuer": "No",
    "entityshellcompany": "false",
    "entitysmallbusiness": "true",
    "entityemerginggrowthcompany": "false",
    "documentannualreport": "true",
    "entityfilenumber": "0-21271",
    "entityaddressstateorprovince": "CO",
    "entityincorporationstatecountrycode": "CO",
    "entityaddressaddressline1": "Bleichenbr&#252;cke 9",
    "entityaddresscityortown": "Hamburg",
    "entityaddresscountry": "DE",
    "entityaddresspostalzipcode": 20354,
    "countryregion": 49,
    "cityareacode": 40,
    "localphonenumber": 6093120,
    "amendmentflag": "false",
    "documentfiscalyearfocus": 2020,
    "documentfiscalperiodfocus": "FY",
    "documenttransitionreport": "false",
    "cash": 15282,
    "prepaidexpensecurrent": 13361,
    "accountsandotherreceivablesnetcurrent": 3317,
    "accountsreceivablenetcurrent": 9858,
    "duefromrelatedpartiescurrent": 6878,
    "assetscurrent": 48696,
    "propertyplantandequipmentnet": 1922,
    "leaseholdimprovementsgross": 74710,
    "assets": 125328,
    "accountspayableandotheraccruedliabilitiescurrent": 119246,
    "duetorelatedpartiescurrent": 42359,
    "debtcurrent": 618568,
    "operatingleaseliabilitycurrent": 11312,
    "liabilitiescurrent": 791485,
    "operatingleaseliabilitynoncurrent": 63721,
    "liabilities": 855206,
    "commonstockvalue": 33027676,
    "additionalpaidincapital": 4513328,
    "treasurystockcommonvalue": 19387,
    "accumulatedothercomprehensiveincomelossnetoftax": 91907,
    "retainedearningsaccumulateddeficit": -37696425,
    "stockholdersequity": -82901,
    "minorityinterest": -646977,
    "stockholdersequityincludingportionattributabletononcontrollinginterest": -729878,
    "liabilitiesandstockholdersequity": 125328,
    "preferredstocksharesauthorized": 10000000,
    "commonstocksharesauthorized": 250000000,
    "commonstocksharesissued": 203355598,
    "commonstocksharesoutstanding": 113800,
    "revenues": 28915,
    "grossprofit": 28915,
    "researchanddevelopmentexpense": 8311,
    "professionalfees": 161036,
    "generalandadministrativeexpense": 39753,
    "depreciationandamortization": 1209,
    "operatingexpenses": 210309,
    "operatingincomeloss": -181394,
    "lossonoutofcourtsettlement": 6714,
    "foreigncurrencytransactiongainlossbeforetax": 3680,
    "interestexpensedebt": 14098,
    "nonoperatingincomeexpense": -17132,
    "incomelossfromcontinuingoperationsbeforeincometaxesdomestic": -198526,
    "profitloss": -198526,
    "incomelossfromcontinuingoperationsattributabletononcontrollingentity": 5785,
    "netincomeloss": -192741,
    "othercomprehensiveincomelossforeigncurrencytransactionandtranslationadjustmentnetoftax": 460,
    "othercomprehensiveincomelosstax": -198066,
    "weightedaveragenumberofshareoutstandingbasicanddiluted": 201746752,
    "sharesoutstanding": 203355598,
    "stockissuedduringperiodvaluenewissues": 15415,
    "stockissuedduringperiodsharesnewissues": 1822000,
    "commonstockissuedoutofcourtsettlement": 44762,
    "stockissuedduringperiodsharesissuedforservices": 2238095,
    "othercomprehensiveincomelossforeigncurrencytranslationadjustmenttax": 460,
    "stockissuedduringperiodvalueissuedforservices": 44762,
    "foreigncurrencytransactiongainlossunrealized": 3680,
    "amortizationofrighttouseasset": 11905,
    "increasedecreaseinaccountsreceivable": -19432,
    "increasedecreaseinprepaidexpense": 275,
    "increasedecreaseinothercurrentassets": 238,
    "increasedecreaseinaccountspayabletrade": -6775,
    "increasedecreaseinduetootherrelatedpartiescurrent": -1710,
    "increasedecreaseinaccountspayablerelatedparties": 15146,
    "increasedecreaseinleaseacquisitioncosts": -12222,
    "netcashprovidedbyusedinoperatingactivities": -168386,
    "paymentstoacquiremachineryandequipment": 3098,
    "netcashprovidedbyusedininvestingactivities": -3098,
    "proceedsfromrelatedpartydebt": 143766,
    "proceedsfromissuanceofcommonstock": 15415,
    "netcashprovidedbyusedinfinancingactivities": 159181,
    "effectofexchangerateoncashandcashequivalents": 132,
    "cashandcashequivalentsperiodincreasedecrease": -12171,
    "cashandcashequivalentsatcarryingvalue": 15282,
    "capitalleaseobligationsincurred": 85696,
    "stockissued1": 44762,
    "equitymethodinvestmentownershippercentage": 0.002,
    "equitymethodinvestmentadditionalinformation": "The Company owned 25 percent of the Joint Venture and accounted for its interest in the Joint Venture using the equity method of accounting. The Company invested $8,508 in the Joint Venture during the year ended June 30, 2011. The Company has written the investment down to $0 for its share of the Joint Venture&#146;s losses, amounting to $112,819 during the calendar year ending December 31, 2014",
    "foreigncurrencyexchangeratetranslation1": 0.904091,
    "depreciation": 1209,
    "concentrationriskpercentage1": 1,
    "relatedpartytransactiontermsandmannerofsettlement": "payments to its joint venture partner (SastoMed GmbH) by the Company of $7,760 per month for research and development consulting services. The agreement was terminated September 30, 2017.",
    "debtinstrumentpaymentterms": "On June 9, 2015, the Company entered into a note payable with the Joint Venture for 32,863 Euros. The note payable accrues interest at 4% annum and is due June 30, 2020.",
    "propertyplantandequipmentgross": 3131,
    "accumulateddepreciationdepletionandamortizationpropertyplantandequipment": 1209,
    "proceedsfromsaleofmachineryandequipment": 1108,
    "debtinstrumentinterestratestatedpercentage": 0.02,
    "interestexpense": 14023,
    "duetorelatedpartiesnoncurrent": 550000,
    "duetootherrelatedpartiesnoncurrent": 618568,
    "sharesissuedpricepershare": 0.009,
    "temporaryequitystockissuedduringperiodvaluenewissues": 15415,
    "liabilityofsharesissued": 38048,
    "treasurystockcommonshares": 53756,
    "treasurystockvalue": 19387,
    "operatinglosscarryforwards": 31700000,
    "operatinglosscarryforwardslimitationsonuse": "The federal and state carryforward amounts expire in varying amounts between 2020 and 2031.",
    "deferredtaxassetsoperatinglosscarryforwards": 7907034,
    "deferredtaxassetsother": 130273,
    "deferredtaxliabilitiesdeferredexpensedeferredfinancingcosts": 10500,
    "deferredtaxassetstaxdeferredexpensereservesandaccrualsimpairmentlosses": 269541,
    "deferredtaxliabilitiesderivatives": 5892,
    "deferredtaxassetsvaluationallowance": 7489372,
    "lesseeoperatingleasedescription": "The Company also leases an automobile under an operating lease. The lease provides for a lease payment of 538Euros ($595) per month beginning June 2018 expiring May 2020.",
    "reimbursementofcostsincurred": 10868,
    "operatingleasesfutureminimumpaymentsduecurrent": 12710,
    "operatingleasesfutureminimumpaymentsdueintwoyears": 12938,
    "operatingleasesfutureminimumpaymentsdueinthreeyears": 13171,
    "operatingleasesfutureminimumpaymentsdueinfouryears": 13408,
    "operatingleasesfutureminimumpaymentsduethereafter": 27547,
    "operatingleasesfutureminimumpaymentsdue": 79774,
    "leaseandrentalexpense": 4741,
    "operatingleaseliability": 75033,
    "lesseeoperatingleasediscountrate": 0.02,
    "lesseeoperatingleaseremainingleaseterm": "P6Y",
    "sharebasedcompensationarrangementbysharebasedpaymentawarddescription": "the Board was authorized to issue up to 10,000,000 shares of common stock (including incentive stock options) to certain eligible employees, directors, and/or consultants of the Company or its subsidiaries"
  },
  {
    "date": "2019-06-29",
    "symbol": "SGBI",
    "period": "FY",
    "entitycentralindexkey": 1104280,
    "currentfiscalyearenddate": "--06-30",
    "entityregistrantname": "SANGUI BIOTECH INTERNATIONAL INC",
    "documenttype": "10-K",
    "documentperiodenddate": "2019-06-30",
    "entitytaxidentificationnumber": "84-1330732",
    "entityfilercategory": "Non-accelerated Filer",
    "entitycurrentreportingstatus": "Yes",
    "entityinteractivedatacurrent": "Yes",
    "entityvoluntaryfilers": "No",
    "entitywellknownseasonedissuer": "No",
    "entityshellcompany": "false",
    "entitysmallbusiness": "true",
    "entityemerginggrowthcompany": "false",
    "documentannualreport": "true",
    "entityfilenumber": "0-21271",
    "entityaddressstateorprovince": "CO",
    "entityincorporationstatecountrycode": "CO",
    "entityaddressaddressline1": "Neuer Wall 54",
    "entityaddresscityortown": "Hamburg",
    "entityaddresscountry": "DE",
    "entityaddresspostalzipcode": 20354,
    "countryregion": 49,
    "cityareacode": 40,
    "localphonenumber": 6093120,
    "documenttransitionreport": "false",
    "amendmentflag": "false",
    "documentfiscalyearfocus": 2019,
    "documentfiscalperiodfocus": "FY",
    "cash": 27453,
    "prepaidexpensecurrent": 9470,
    "accountsandotherreceivablesnetcurrent": 6852,
    "accountsreceivablenetcurrent": 29525,
    "duefromrelatedpartiescurrent": 5671,
    "assetscurrent": 78971,
    "assets": 78971,
    "accountspayableandotheraccruedliabilitiescurrent": 164145,
    "duetorelatedpartiescurrent": 28458,
    "debtcurrent": 478357,
    "liabilitiescurrent": 670960,
    "commonstockvalue": 32967499,
    "additionalpaidincapital": 4513328,
    "treasurystockcommonvalue": 19387,
    "accumulatedothercomprehensiveincomelossnetoftax": 91447,
    "retainedearningsaccumulateddeficit": -37503684,
    "stockholdersequity": 49203,
    "minorityinterest": -641192,
    "stockholdersequityincludingportionattributabletononcontrollinginterest": -591989,
    "liabilitiesandstockholdersequity": 78971,
    "revenues": 88001,
    "grossprofit": 88001,
    "researchanddevelopmentexpense": 27226,
    "professionalfees": 209516,
    "generalandadministrativeexpense": 188894,
    "operatingexpenses": 425636,
    "operatingincomeloss": -337635,
    "foreigncurrencytransactiongainlossbeforetax": 6807,
    "interestexpensedebt": 11686,
    "nonoperatingincomeexpense": -4879,
    "incomelossfromcontinuingoperationsbeforeincometaxesdomestic": -342514,
    "profitloss": -342514,
    "incomelossfromcontinuingoperationsattributabletononcontrollingentity": 18938,
    "netincomeloss": -323576,
    "othercomprehensiveincomeforeigncurrencytransactionandtranslationgainlossarisingduringperiodnetoftax": -1474,
    "othercomprehensiveincomelosstax": -343988,
    "weightedaveragenumberofshareoutstandingbasicanddiluted": 197127973,
    "sharesoutstanding": 199295503,
    "stockissuedduringperiodvaluenewissues": 84491,
    "stockissuedduringperiodsharesnewissues": 6500000,
    "stockissuedduringperiodvalueissuedforservices": 18651,
    "stockissuedduringperiodsharesissuedforservices": 844000,
    "othercomprehensiveincomelossforeigncurrencytranslationadjustmenttax": -1474,
    "issuanceofstockandwarrantsforservicesorclaims": 18652,
    "foreigncurrencytransactiongainlossunrealized": 6807,
    "increasedecreaseinaccountsreceivable": -18411,
    "increasedecreaseinprepaidexpense": -12856,
    "increasedecreaseinothercurrentassets": 4769,
    "increasedecreaseinaccountspayabletrade": -23873,
    "increasedecreaseinduetootherrelatedpartiescurrent": 1221,
    "increasedecreaseinaccountspayablerelatedparties": 9905,
    "netcashprovidedbyusedinoperatingactivities": -316918,
    "proceedsfromrelatedpartydebt": 878606,
    "repaymentsofrelatedpartydebt": 598974,
    "proceedsfromissuanceofcommonstock": 84491,
    "repaymentsofunsecureddebt": 37608,
    "netcashprovidedbyusedinfinancingactivities": 326515,
    "effectofexchangerateoncashandcashequivalents": -3087,
    "cashandcashequivalentsperiodincreasedecrease": 6510,
    "cashandcashequivalentsatcarryingvalue": 27453,
    "interestpaid": 2520,
    "equitymethodinvestmentownershippercentage": 0.9,
    "equitymethodinvestmentadditionalinformation": "Effective from June 18, 2018 Sangui BioTech GmbH together with Sastomed GmbH founded Sangui Know-How- und Patentverwertungsgesellschaft mbH &amp; Co. KG (“Sangui KG”). Sangui KG is a limited partnership, with Sangui BioTech GmbH as the general partner (owing 99.8%) and Sastomed GmbH as a limited partner (owning 0.2%).",
    "foreigncurrencyexchangeratetranslation1": 0.878005,
    "concentrationriskpercentage1": 0.99,
    "commonstocksharesoutstanding": 113800,
    "relatedpartytransactiontermsandmannerofsettlement": "payments to its joint venture partner (SastoMed GmbH) by the Company of $7,760 per month for research and development consulting services. The agreement was terminated September 30, 2017.",
    "debtinstrumentpaymentterms": "On June 9, 2015, the Company entered into a note payable with the Joint Venture for 32,863 Euros.  The note payable accrues interest at 4% annum and is due June 30, 2019.",
    "proceedsfromsaleofmachineryandequipment": 1108,
    "debtinstrumentcarryingamount": 23584,
    "preferredstocksharesauthorized": 10000000,
    "commonstocksharesauthorized": 250000000,
    "sharesissuedpricepershare": 0.013,
    "temporaryequitystockissuedduringperiodvaluenewissues": 84491,
    "stockissuedduringperiodsharesother": 18652,
    "operatinglosscarryforwards": 35400000,
    "operatinglosscarryforwardslimitationsonuse": "The federal and state carryforward amounts expire in varying amounts between 2019 and 2030.",
    "deferredtaxassetsoperatinglosscarryforwards": -7851921,
    "deferredtaxassetsother": 130273,
    "deferredtaxliabilitiesdeferredexpensedeferredfinancingcosts": 10500,
    "deferredtaxassetstaxdeferredexpensereservesandaccrualsimpairmentlosses": 269541,
    "deferredtaxliabilitiesderivatives": 5892,
    "deferredtaxassetsvaluationallowance": 7434259,
    "lesseeoperatingleasedescription": "The Company leases office facilities from an unrelated third party at Euro 685 per month. The office lease contract is maintained on a month-to-month basis",
    "othercommitmentsdescription": ", Sangui also granted a issuing of 2,238,095 of its shares to the employee in addition to a license fee on the revenues generated by the license agreement with Sastomed",
    "paymentsforfees": 10868,
    "otheraccountspayableandaccruedliabilities": 27180,
    "sharebasedcompensationarrangementbysharebasedpaymentawarddescription": "the Board was authorized to issue up to 1,000,000 shares of common stock to certain eligible employees of the Company or its subsidiaries. All of these shares were issued pursuant to the plan prior to June 30, 2007",
    "debtinstrumentdescription": "The note payable accrues interest at 4% annum and is due June 30, 2019.   Accordingly, the note payable and accrued interest of 34,282 Euros"
  },
  {
    "date": "2018-06-29",
    "symbol": "SGBI",
    "period": "FY",
    "entityregistrantname": "SANGUI BIOTECH INTERNATIONAL INC",
    "documenttype": "10-K",
    "documentperiodenddate": "2018-06-30",
    "tradingsymbol": "sgbi",
    "amendmentflag": "false",
    "entitycentralindexkey": 1104280,
    "currentfiscalyearenddate": "--06-30",
    "entitycommonstocksharesoutstanding": 192951503,
    "entityfilercategory": "Non-accelerated Filer",
    "entitycurrentreportingstatus": "No",
    "entityvoluntaryfilers": "No",
    "entitywellknownseasonedissuer": "No",
    "documentfiscalyearfocus": 2018,
    "documentfiscalperiodfocus": "FY",
    "cash": 20943,
    "prepaidtaxes": 2143,
    "accountsreceivablenet": 49107,
    "notesreceivablerelatedparties": 7062,
    "prepaidexpenseandotherassets": 22774,
    "assetscurrent": 102029,
    "assets": 102029,
    "accountspayableandaccruedliabilitiescurrentandnoncurrent": 189739,
    "prepaidinterest": 19088,
    "notespayable": 40025,
    "notespayablerelatedpartiescurrentandnoncurrent": 204321,
    "liabilitiescurrent": 453173,
    "commonstockvalue": 32864356,
    "additionalpaidincapital": 4513328,
    "treasurystockvalue": -19387,
    "accumulatedothercomprehensiveincomelossnetoftax": 92921,
    "retainedearningsaccumulateddeficit": -37180108,
    "noncontrollinginterestinvariableinterestentity": -622254,
    "stockholdersequity": -351144,
    "liabilitiesandstockholdersequity": 102029,
    "revenues": 77152,
    "costofgoodssold": 62,
    "grossprofit": 77090,
    "researchanddevelopmentexpense": 23003,
    "professionalfees": 121478,
    "generalandadministrativeexpense": 140654,
    "operatingexpenses": 285135,
    "operatingincomeloss": -208045,
    "effectofexchangerateoncash": 549,
    "interestexpense": -8307,
    "otheroperatingincomeexpensenet": -7758,
    "incomelossfromcontinuingoperationsbeforeincometaxesextraordinaryitemsnoncontrollinginterest": -215803,
    "netincomeloss": -245109,
    "weightedaveragenumberofsharesissuedbasic": 188204782,
    "profitloss": -215803,
    "foreigncurrencytransactiongainbeforetax": 99,
    "increasedecreaseinaccountsreceivable": -48628,
    "increasedecreaseinprepaidexpense": 4282,
    "increasedecreaseinincometaxesreceivable": 1113,
    "increasedecreaseinaccountspayableandaccruedliabilities": -1254,
    "increasedecreaseinaccountspayablerelatedparties": 6873,
    "increasedecreaseincustomeradvances": -443,
    "netcashprovidedbyusedinoperatingactivities": -253761,
    "proceedsfromnotespayable": 90113,
    "proceedsfromissuanceofcommonstock": 154489,
    "netcashprovidedbyusedinfinancingactivities": 244602,
    "effectofexchangerateoncashandcashequivalents": -26888,
    "cashperiodincreasedecrease": -36047,
    "cashandcashequivalentsatcarryingvalue": 20943,
    "interestpaid": 1647
  }
]